- Health and wellness company HempFusion Wellness, Inc. launched its IPO Jan. 6 with the ticker CBD.U, and also trades in the US under the symbol CBDHF
- The company distributes its brands HempFusion, Probulin Probiotics, Biome Research and HF Labs to 4,000 retailers in every state as well as select international locales, and is strategically planning for expansion
- Despite the economic battering some industries have experienced as a result of the global pandemic, hemp and CBD continue to see consumer use trends holding stable with forecasts for new market growth in coming years
- HempFusion is focused on regulatory compliance with industry safety and quality standards, and is also a lead sponsor and participant in CBD liver-impact study
- HempFusion has been included in two leading cannabis & hemp-derived CBD focused exchange- ETFs, AdvisorShares Pure US Cannabis ETF (NYSE: MSOS) and AdvisorShares Pure Cannabis ETF (NYSE: YOLO)
On Jan. 6, HempFusion Wellness (TSX: CBD.U) (OTC: CBDHF) launched an IPO and listing of its common shares and certain other securities on Canada’s TSX exchange, making the company the first U.S.-based cannabidiol (“CBD”) product manufacturer to list on the TSX as it snared the ticker CBD.U (https://ibn.fm/TxxBW). Subsequently the company received its US symbol: CBDHF.
Amid the spread of pandemic conditions worldwide, hemp farmers found their robust expectations of a “green rush” following legalization efforts in the United States to be in a cooling trend, largely because of an oversupplied market as the agricultural industry sorts out its balance point in an emerging product phase (https://ibn.fm/3B9WG).
Even so, surveys have found that hemp and CBD use trends are continuing on point, possibly as a result of individuals’ efforts to manage stresses related to the health crisis, its economic fallout, and contentious politically motivated parties circling the field (https://ibn.fm/4etQU).
The steadiness of the hemp consumer trends and the potential for a new rush rebound once pandemic-spawned social restrictions subside are good news for companies like Denver-based HempFusion Wellness, which incorporated in late 2015 and has seen its sails fill over the past four years as strategic acquisition and relentless retail channel penetration have driven its revenues upward.
The pandemic has forced consumers to rely more heavily than ever on e-commerce and Internet-based video communication platforms to conduct business and manage personnel remotely, which in turn has created ample opportunity for young companies to compete so long as they can manage the challenges of production pace while they attempt to scale up.
HempFusion’s CBD and probiotic products include a family of brands such as HempFusion, Probulin Probiotics, Biome Research and HF Labs, that are distributed to approximately 4,000 retailers in every state as well as select international locales. The company is strategically planning its expansion to potentially add a variety of product offerings including CBD-based beverages, edibles, pet products and more.
Grandview Research analysts anticipate that CBD-based pet products will see a CAGR of 40.3 percent between 2020 and 2027 (https://ibn.fm/E9yvl), while Data Bridge Market Research predicts CBD edibles will grow at a CAGR of 24.30 percent during the same period (https://ibn.fm/9CWzK).
The CBD-based beverage market, still in its infancy, grew 168 percent YOY between December 2018 and 2019, according to BDS Analytics (https://ibn.fm/ZpHru) and Grandview Research notes the sector is expected to grow at a CAGR of 17.8 percent through 2025.
Among the condition-specific OTC product markets where HempFusion is now operating, pain products are projected to see a CAGR of 7.4 percent between 2018 and 2025, eczema products are predicted to increase to $13.6 billion by 2026, the acne and beauty product sector is already estimated at $1.08 trillion and the first aid products segment was generating over $650 million in sales as of last year’s report (https://ibn.fm/Ouvkb).
“Completion of (the) … initial public offering will accelerate our ability to scale HempFusion’s operations both domestically and internationally, drive accelerated growth within all our distribution channels, and significantly expand our marketing initiatives,” CEO Dr. Jason Mitchell stated recently (https://ibn.fm/Er4wO).
For more information, visit the company’s website at www.HempFusion.com/Corporate-Information and contact the team at ir@hempfusion.com.
NOTE TO INVESTORS: The latest news and updates relating to HempFusion are available in the company’s newsroom at https://ibn.fm/HempFusion
About MissionIR
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
